Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upcoming Medical Meetings
"Data presentations for avapritinib, BLU-667 and BLU-782 at important upcoming medical and scientific meetings reflect the power of our scientific platform to rapidly and reproducibly advance highly selective kinase medicines against diverse, difficult-to-drug targets," said
Avapritinib: Gastrointestinal Stromal Tumors (GIST)
2018
Poster Presentation Title: Correlation of ctDNA and response in patients with PDGFRα D842 GIST treated with avapritinib
Session Title: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Session Date & Time: Monday, October 22, 2018 from
Presenter:
Abstract Number: 5100
Trial in
Session Title: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Session Date & Time: Monday, October 22, 2018 from
Presenter:
Abstract Number: 4534
2018
Oral Presentation Title: Avapritinib is Highly Active and Well-Tolerated in Patients with Advanced GIST Driven by Diverse Variety of Oncogenic Mutations in KIT and PDGFRA
Session Title: Session 3 – GIST
Session Date & Time:
Presenter:
Abstract Number: 3027631
BLU-667: RET-Altered Solid Tumors
IASLC 19th
Late-Breaking Oral Presentation Title: Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement
Session Title: New Therapies and Emerging Data in ALK, EGFR and ROS1
Session Date & Time:
Presenter:
Abstract Number: MA26.03
88th Annual Meeting of the
Oral Presentation Title: Clinical Activity of Selective RET Inhibitor, BLU-667, in Advanced RET-Altered Thyroid Cancers; Updated Results from the Phase 1 ARROW Study
Session Title: Translational Short Call Oral Abstracts
Session Date & Time:
Presenter:
Abstract Number: 5
BLU-782: Fibrodysplasia Ossificans Progressiva
2018
Oral Presentation Title: BLU-782; a highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva
Session Title: Plenary Oral 2 – Translational Highlights II
Session Date & Time:
Presenter:
Presentation Number: 1078
About
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-showcases-broad-portfolio-of-highly-selective-investigational-kinase-medicines-with-presentations-at-upcoming-medical-meetings-300717347.html
SOURCE
Investor and Media Relations Contacts, Kristin Hodous, 617-714-6674, KHodous@blueprintmedicines.com; Jim Baker, 617-844-8236, JBaker@blueprintmedicines.com